Adults with cystic fibrosis experience higher pain prevalence and severity compared to healthy controls, with significant unmet needs in pain management. New study highlights critical gaps in care.

Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

Ann & Robert H. Lurie Children’s Hospital of Chicago launched a newborn screening awareness campaign, with signage on public transit and billboards across Chicago urging parents to contact their child ...

Receiving a diagnosis for any disease/condition is not an easy experience. One organization hopes to make patients newly diagnosed with pulmonary fibrosis feel supported during this time via a new ...

Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and often fatal lung disease characterized by the scarring (fibrosis) of lung tissue, ...

When cystic fibrosis hits your lungs hard, hit back. Everything you need to know about getting your lungs back into shape is ...

Though most hiccups are harmless and fade away quickly, some can be painful or persistent. To figure out why, experts suggest paying attention to other symptoms that might accompany those odd ...

Women are being forced to consider “flying or dying” as they wait up to four months to get a mammogram following the ...

Cystic fibrosis, a genetic disease that attacks the lungs, affects roughly 1 in 3,000 people, and cystic fibrosis-related diabetes (CFRD) is its most common complication, a rare and unique type ...

In December, the FDA approved Vertex’s vanzacaftor, tezacaftor and deutivacaftor (Alyftrek) for the treatment of cystic fibrosis in patients with at least one F508del mutation or another ...

Ivacaftor Oral Granules, 25 mg, 50 mg and 75 mg per unit dose packet are indicated for cystic fibrosis treatment in patients aged 4 months and older. Mumbai: Global pharma major, Lupin Limited, has ...

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in upfront and near-term payments for global rights to an asset that is ...